[1]NMPA.药用原辅材料备案管理规定(征求意见稿)国食药监注函[2010]183号[EB/OL]. (2010-09-16) [2019-02-25]. http://www.nmpa.gov.cn/WS04/CL2101/228772.html
[2]NMPA.国家食品药品监督管理局关于印发加强药用辅料监督管理有关规定的通知 国食药监办[2012]212号[EB/OL]. (2012-08-01) [2019-02-25]. http://www. nmpa. gov. cn/WS04/CL2196/323909. html
[3]NMPA.国务院关于改革药品医疗器械审评审批制度的意见国发〔2015〕44号 [EB/OL]. (2015-08-18) [2019-02-25]. http://www.nmpa.gov.cn/WS04/CL2079/333413.html
[4]NMPA.总局关于药包材药用辅料与药品关联审评审批有关事项的公告(2016年第134号) [EB/OL]. (2016-08-09) [2019-02-25]. http://www.nmpa.gov.cn/WS04/CL2182/300197.html
[5]NMPA.关于印发药用辅料注册申报资料要求的函 食药监注函[2005]61号[EB/OL]. (2005-06-21) [2019-02-25]. http://www. nmpa. gov. cn/WS04/CL2196/323505. html
[6]NMPA.药品注册管理办法 局令第28号 [EB/OL]. (2007-07-10) [2019-03-14]. http://www.nmpa.gov.cn/WS04/CL2174/300629.html
[7]NMPA. 关于印发已上市化学药品变更研究的技术指导原则的通知 国食药监注[2008]242号[EB/OL]. (2008-05-15) [2019-03-14]. http://www.nmpa.gov.cn/WS04/CL2196/323682.html
[8]NMPA. 总局办公厅公开征求《原料药、药用辅料及药包材与药品制剂共同审评审批管理办法(征求意见稿)》意见 [EB/OL]. (2017-12-04) [2019-02-25]. http://www.nmpa.gov.cn/WS04/CL2101/228891.html
[9]IPEC中国协会关于公开征求《药用辅料变更研究技术指南(征求意见稿)》意见的通知 [EB/OL]. (2017-12-28) [2019-02-25]. http://www. ipec-china. org/info/cn/ipec-china-news/guide/View. aspxnid=8958
[10]杨悦.药用原辅料和包装材料关联审评改革 [M]. 北京:中国医药科技出版社,2018.
[11]王建英.美国药品申报与法规管理 [M]. 北京:中国医药科技出版社,2005: 296-297.
[12]FDA.Guidance for Industry: Changes to an Approved NDA or ANDA [EB/OL]. (2004-04) [2018-12-03]. https://www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM077097. pdf
[13]FDA.SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation [EB/OL]. (1995-11) [2019-02-22]. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070636. pdf
[14]USP40/NF35, General Information Chapter <1195> Significant Change Guide for Bulk Pharmaceutical Excipients[S]. 2017.
[15]EDQM. Guideline on Requirements for Revision/Renewal of Certificates of Suitability to the European Pharmacopoeia Monographs [EB/OL]. (2018-09) [2019-01-22]. https://www.edqm.eu/sites/default/files/pa_ph_cep_04_2_7rcorr. pdf
[16]EC COMMISSION REGULATION (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products [EB/OL]. (2008-12-24) [2019-01-22]. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2008_1234_cons_2012-11-02/reg_2008_1234_cons_2012-11-02_en.pdf
[17]EC. Guidelines on the details of the various categories of variations, on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products and on the documentation to be submitted pursuant to those procedures [EB/OL]. (2013-08-02) [2019-01-22]. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/c_2013_223/c_2013_2804_en.pdf
[18]PMDA.Guideline on Utilization of Master File for Drug Substances, etc. [EB/OL]. (2005-02) [2018-12-08]. http://www.pmda.go.jp/files/000153843.pdf
[19]向星萍,陈永法. MAH制度下我国药用辅料审评审批制度改革研究[J]. 现代商贸工业,2018,(19):161-163.
[20]谭燕美,由春娜,董敏.我国药用辅料关联审评审批政策的剖析与建议[J]. 中国医药工业杂志,2017,48(8):1208-1213.